Skip to main content
SupplementScience

Benefits of Bergamot (Citrus Bergamot)

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • LDL cholesterol reduction — Mollace et al. (2011) found that 1000mg BPF daily reduced LDL by 36% after 30 days in patients with hyperlipidemia, with effects comparable to moderate-dose rosuvastatin.
  • Triglyceride lowering — the same study reported triglyceride reductions of 39% at the 1000mg dose, exceeding the effect typically seen with statin monotherapy.
  • HDL improvement — bergamot extract increased HDL cholesterol by 40% in the Mollace et al. trial, likely through enhanced reverse cholesterol transport and anti-oxidation of HDL particles.
  • Metabolic syndrome support — Gliozzi et al. (2014) demonstrated that bergamot polyphenols significantly improved fasting glucose, insulin sensitivity, and waist circumference in metabolic syndrome patients.

What the Research Says

Bergamot research has accelerated rapidly since the pivotal Mollace et al. (2011) study demonstrated impressive LDL and triglyceride reductions in hyperlipidemic patients. Gliozzi et al. (2014) extended these findings to metabolic syndrome, showing improvements across multiple cardiometabolic markers. The mechanisms are well-characterized: brutieridin and melitidin directly inhibit HMG-CoA reductase (the same target as statins), while other polyphenols activate AMPK and improve glucose uptake. Most studies use Calabrian bergamot extracts, and product quality varies significantly — standardized BPF from authenticated Citrus bergamia sources provides the most reliable results.

References

  1. (). Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. DOI
  2. (). Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. International Journal of Cardiology. DOI